Ivan N. Rich, PhD is Founder, Chairman and CEO of HemoGenix®, Inc and adjunct Professor in the Department of Biology at the University of Colorado at Colorado Springs. In 1994, he founded and was CEO of "Specialized Culture Technologies", a company specializing in unique tissue culture equipment and accessories in Germany. Today, HemoGenix® continues the sales and marketing of the POC in vitro culture chamber systems and accessories, and is the sole distributor of these German-made products in the U.S.A and Canada. Dr. Rich obtained his BSc in biochemistry at the University of Sussex in Brighton/Falmer, England in 1973. He completed his PhD in 1978 at the University of Ulm in Ulm, Germany and completed a second thesis in Experimental Hematology in 1995. His postdoctoral research was performed at the University of Chicago between 1981 and 1983 with Dr. Eugene Goldwasser who, together with his associates, was responsible for obtaining the first partial amino acid sequence of purified erythropoietin (EPO) that eventually led to the production of the first human recombinant EPO used around the world to alleviate the symptoms of chronic anemia. Dr. Rich moved to the United States in 1996.
Dr. Rich has authored 48 peer-reviewed publications, 32 reviews and book chapters and has attended and presented his research at more than 200 international conferences. He also organized and edited conference proceedings for a NATO Advanced Research Workshop. Together with Terrance R.J. Lappin, PhD, Professor of Hematology at Queen's University in Belfast, Northern Ireland, he also organized and edited the proceedings of a New York Academy of Science Workshop on erythropoietin.
Ivan Rich belongs to several societies including The American Society of Hematology (ASH), The International Society of Experimental Hematology (ISEH), The British Society of Haematology, International Society for Stem Cell Research (ISSCR), The International Society of Cellular Therapy (ISCT), AABB (American Association of Blood Banks), The Society of Toxicology (SOT) and The Society of Biomolecular Screening (SBS). He is also a reviewer for many scientific journals and grant agencies around the world.